First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

Leora Horn , Aaron S. Mansfield , Aleksandra Szczęsna , Leora Horn , Aaron S. Mansfield , Aleksandra Szczęsna , Libor Havel , Maciej Krzakowski , Maximilian J. Hochmair , Florian Huemer , György Losonczy , Melissa L. Johnson , Makoto Nishio , Martin Reck , Tony Mok , Sivuonthanh Lam , David S. Shames , Juan Liu , Beiying Ding , Ariel López-Chávez , Fairooz F. Kabbinavar , Wei Lin , Alan Sandler , Stephen V. Liu
2018 New England Journal of Medicine 3,263 citations

Abstract

The addition of atezolizumab to chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer resulted in significantly longer overall survival and progression-free survival than chemotherapy alone. (Funded by F. Hoffmann-La Roche/Genentech; IMpower133 ClinicalTrials.gov number, NCT02763579 .).

Keywords

AtezolizumabChemotherapyLung cancerCytotoxic T cellCancer researchProgrammed cell deathPD-L1CytotoxicityOncologyMedicineImmunotherapyCancerInternal medicineBiologyApoptosisNivolumabIn vitroBiochemistry

Affiliated Institutions

Related Publications

Publication Info

Year
2018
Type
article
Volume
379
Issue
23
Pages
2220-2229
Citations
3263
Access
Closed

External Links

View on DOI.org

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

3263
OpenAlex

Cite This

Leora Horn, Aaron S. Mansfield, Aleksandra Szczęsna et al. (2018). First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. New England Journal of Medicine , 379 (23) , 2220-2229. https://doi.org/10.1056/nejmoa1809064

Identifiers

DOI
10.1056/nejmoa1809064